Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: Biases and evolution over time
dc.contributor.author | Ioannidis, J. P. A. | en |
dc.contributor.author | Polycarpou, A. | en |
dc.contributor.author | Ntais, C. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Ioannidis, J. P. A. | en |
dc.creator | Polycarpou, A. | en |
dc.creator | Ntais, C. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:41Z | |
dc.date.available | 2018-06-22T09:53:41Z | |
dc.date.issued | 2003 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41971 | |
dc.description.abstract | We systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42 661 patients), no regimens were compared in >6 studies. Twenty-six trials (10%) found statistically significant differences in survival between the compared arms. Only five reported the randomisation mode, and four reported adequate allocation concealment; nine performed unaccounted interim analyses. Statistical significance was more common in larger (P=0.003), more recent studies (P=0.031), and trials from countries with only one published eligible study (P=0.008). Increased reported median survival was independently associated with platinum and/or taxane and combination regimens, but also with the year of publication, smaller sample size, and larger representation of non-stage IV patients and patients with a better performance status. The proportion of enrolled patients with a performance status of 2 or worse decreased significantly over time (12.9% per decade, P<0.001). Randomised evidence in this field is fragmented and subject to considerable selection biases. © 2003 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | European journal of cancer | en |
dc.subject | Bias | en |
dc.subject | Meta-analysis | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Vinblastine | en |
dc.subject | Controlled study | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Gemcitabine | en |
dc.subject | Navelbine | en |
dc.subject | Drug dose regimen | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Statistical significance | en |
dc.subject | Review | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Information retrieval | en |
dc.subject | Survival | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Lomustine | en |
dc.subject | Sample size | en |
dc.subject | Data analysis | en |
dc.subject | Statistical analysis | en |
dc.subject | Mitomycin c | en |
dc.subject | Disease association | en |
dc.subject | Lung cancer | en |
dc.subject | Ifosfamide | en |
dc.subject | Cancer classification | en |
dc.subject | Evaluation | en |
dc.subject | Health status | en |
dc.subject | Advanced stage | en |
dc.subject | Randomised controlled trials | en |
dc.subject | Non-small cell | en |
dc.subject | Performance status | en |
dc.subject | Platinum | en |
dc.subject | Selection bias | en |
dc.subject | Taxane | en |
dc.subject | Vindesine | en |
dc.title | Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: Biases and evolution over time | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0959-8049(03)00571-9 | |
dc.description.volume | 39 | |
dc.description.issue | 16 | |
dc.description.startingpage | 2278 | |
dc.description.endingpage | 2287 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |